Marina Talamonti (M Talamonti)

Scopus Author ID ResearcherID Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2016-2024
Publications (10 Years): 40

Top Venues

Journal of clinical medicine

Expert opinion on biological therapy

Journal of the European Academy of Dermatology and Venereology : JEADV

Cell cycle (Georgetown, Tex.)

University of Rome Tor Vergata

University of Rome Tor Vergata (MSC)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Rome Tor Vergata

Italy

Researcher/MD :: Dermatology

Education History

University of Rome Tor Vergata

Italy

MSC

Publications

Lorenzo Marcelli, Alfredo Belcastro, Marina Talamonti, Claudia Paganini, Angela Fico, Lorenzo Savastano, Cosimo Di Raimondo, Laura Vellucci, Luca Bianchi, Marco Galluzzo
Characterization of Super-Responder Profile in Chronic Plaque Psoriatic Patients under Guselkumab Treatment: A Long-Term Real-Life Experience. Journal of clinical medicine 13 (17) (2024)
Claudia Paganini, Virginia Maffei, Laura Vellucci, Marina Talamonti, Alessandra Petruzzellis, Lorenzo Le Pera, Cosimo Di Raimondo, Luca Bianchi, Marco Galluzzo
Efficacy and Safety of Dupilumab in the Treatment of Hand Eczema: A Retrospective Study. Journal of clinical medicine 13 (7) (2024)
Claudia Paganini, Virginia Maffei, Laura Vellucci, Marina Talamonti, Alessandra Petruzzellis, Lorenzo Le Pera, Cosimo Di Raimondo, Luca Bianchi, Marco Galluzzo
Efficacy and Safety of Dupilumab in the Treatment of Hand Eczema: A Retrospective Study. Journal of clinical medicine 13 (7) (2024)
Claudia Paganini, Virginia Maffei, Laura Vellucci, Marina Talamonti, Alessandra Petruzzellis, Lorenzo Le Pera, Cosimo Di Raimondo, Luca Bianchi, Marco Galluzzo
Efficacy and Safety of Dupilumab in the Treatment of Hand Eczema: A Retrospective Study. Journal of clinical medicine 13 (7) (2024)
Marco Galluzzo, Emanuele Trovato, Marina Talamonti, Giacomo Caldarola, Lucia Di Nardo, Laura Lazzeri, Cristina Mugheddu, Martina Burlando, Riccardo Balestri, Nicoletta Bernardini, Gabriele Biondi, Laura Vellucci, Filomena Russo, Clara De Simone, Claudia Paganini, Giulia Rech, Emanuele Claudio Cozzani, Laura Atzori, Maria Antonia Montesu, Concetta Potenza, Andrea Chiricozzi, Pietro Rubegni
Long-Term Persistence Rate of Secukinumab in Psoriatic Patients: A Six-Year Multicenter, Real-World Experience, Retrospective Study. Journal of clinical medicine 13 (13) (2024)
Marina Talamonti, Marco Galluzzo
Ocular complications in patients with psoriasis: Is dry eye associated with psoriasis? Journal of the European Academy of Dermatology and Venereology : JEADV 38 (8) (2024)
Claudia Paganini, Marina Talamonti, Virginia Maffei, Cosimo Di Raimondo, Luca Bianchi, Marco Galluzzo
Dupilumab for Treatment of Prurigo Nodularis: Real-Life Effectiveness for up to 84 Weeks. Journal of clinical medicine 13 (3) (2024)
Claudia Paganini, Sara Spelta, Lorenzo Tofani, Marina Talamonti, Luca Bianchi, Marco Coassin, Antonio Di Zazzo, Marco Galluzzo
Impact of Upadacitinib on Atopic Keratoconjunctivitis Exacerbated by Dupilumab Treatment in Atopic Dermatitis Patients: A Prospective Dermatological and Ophthalmological Clinical Evaluation in Common Clinical Practice. Journal of clinical medicine 13 (13) (2024)
Marco Galluzzo, Emanuele Trovato, Marina Talamonti, Giacomo Caldarola, Lucia Di Nardo, Laura Lazzeri, Cristina Mugheddu, Martina Burlando, Riccardo Balestri, Nicoletta Bernardini, Gabriele Biondi, Laura Vellucci, Filomena Russo, Clara De Simone, Claudia Paganini, Giulia Rech, Emanuele Claudio Cozzani, Laura Atzori, Maria Antonia Montesu, Concetta Potenza, Andrea Chiricozzi, Pietro Rubegni
Long-Term Persistence Rate of Secukinumab in Psoriatic Patients: A Six-Year Multicenter, Real-World Experience, Retrospective Study. Journal of clinical medicine 13 (13) (2024)
Claudia Paganini, Marina Talamonti, Virginia Maffei, Cosimo Di Raimondo, Luca Bianchi, Marco Galluzzo
Dupilumab for Treatment of Prurigo Nodularis: Real-Life Effectiveness for up to 84 Weeks. Journal of clinical medicine 13 (3) (2024)
Claudia Paganini, Sara Spelta, Lorenzo Tofani, Marina Talamonti, Luca Bianchi, Marco Coassin, Antonio Di Zazzo, Marco Galluzzo
Impact of Upadacitinib on Atopic Keratoconjunctivitis Exacerbated by Dupilumab Treatment in Atopic Dermatitis Patients: A Prospective Dermatological and Ophthalmological Clinical Evaluation in Common Clinical Practice. Journal of clinical medicine 13 (13) (2024)
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, Rosa Giuseppa Angileri, Federico Bardazzi, Nicoletta Bernardini, Martina Burlando, Carlo G Carrera, Andrea Chiricozzi, Paolo Dapavo, Valentina Dini, Gabriella Fabbrocini, Francesca Maria Gaiani, Marco Galluzzo, Claudia Giofré, Claudio Guarneri, Francesco Loconsole, Giovanna Malara, Lorenzo Marcelli, Matteo Megna, Stefano Piaserico, Marina Talamonti, Antonio Costanzo, Alessandra Narcisi
Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS). Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Marina Talamonti, Filomena Russo, Giovanna Malara, Katharina Hansel, Manuela Papini, Angelo Cattaneo, Aurora Parodi, Andrea Chiricozzi, Piergiorgio Malagoli, Federico Bardazzi, Valeria Brazzelli, Paolo Dapavo, Paolo Gisondi, Cristina Zane, Concetta Potenza, Franca Cantoresi, Maria-Concetta Fargnoli, Sara Trevisini, Pina Brianti, Leonardo Pescitelli, Giovanni Gigante, Marta Bartezaghi, Luisa Caputo, Elisabetta Aloisi, Antonio Costanzo, null null
Efficacy and Safety of Secukinumab in Elderly Patients with Moderate to Severe Plaque-Type Psoriasis: Post-Hoc Analysis of the SUPREME Study. Clinical, cosmetic and investigational dermatology 16 (2023)
Luigi Gargiulo, Luciano Ibba, P Malagoli, R G Angileri, F Bardazzi, Nicoletta Bernardini, M Burlando, C G Carrera, Andrea Chiricozzi, P Dapavo, Valentina Dini, G Fabbrocini, F M Gaiani, Marco Galluzzo, C Giofré, C Guarneri, F Loconsole, G Malara, L Marcelli, Matteo Megna, Stefano Piaserico, Marina Talamonti, Antonio Costanzo, A Narcisi
Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: a 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS). Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, Rosa Giuseppa Angileri, Federico Bardazzi, Nicoletta Bernardini, Martina Burlando, Carlo G Carrera, Andrea Chiricozzi, Paolo Dapavo, Valentina Dini, Gabriella Fabbrocini, Francesca Maria Gaiani, Marco Galluzzo, Claudia Giofré, Claudio Guarneri, Francesco Loconsole, Giovanna Malara, Lorenzo Marcelli, Matteo Megna, Stefano Piaserico, Marina Talamonti, Antonio Costanzo, Alessandra Narcisi
Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS). Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Marco Galluzzo, Lorenzo Marcelli, Laura Vellucci, Claudia Paganini, Virginia Maffei, Lorenzo Tofani, Alfredo Belcastro, Luca Bianchi, Marina Talamonti
Guselkumab for treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and drug-survival for up to 148 weeks. Expert opinion on biological therapy (2023)
Marco Galluzzo, Laura Vellucci, Lorenzo Marcelli, Claudia Paganini, Luca Bianchi, Marina Talamonti
Deucravacitinib, a selective tyrosine kinase 2 inhibitor, for the treatment of moderate-to-severe plaque psoriasis. Expert opinion on pharmacotherapy (2023)
Marco Galluzzo, Laura Vellucci, Lorenzo Marcelli, Claudia Paganini, Luca Bianchi, Marina Talamonti
Deucravacitinib, a selective tyrosine kinase 2 inhibitor, for the treatment of moderate-to-severe plaque psoriasis. Expert opinion on pharmacotherapy (2023)
Marco Galluzzo, Marina Talamonti, Arnaldo Cioni, Virginia Maffei, Ruslana Gaeta Shumak, Lorenzo Tofani, Luca Bianchi, Elena Campione
Efficacy of Tildrakizumab for the Treatment of Difficult-to-Treat Areas: Scalp, Nail, Palmoplantar and Genital Psoriasis. Journal of clinical medicine 11 (9) (2022)
Marco Galluzzo, Marina Talamonti, Laura Atzori, Federico Bardazzi, Campanati Anna, Antonella Di Cesare, Federico Diotallevi, Maria Laura Flori, Cristina Mugheddu, Annamaria Offidani, Stefano Piaserico, Filomena Russo, Lidia Sacchelli, Luca Bianchi, Francesca Prignano
Secukinumab for the treatment of palmoplantar psoriasis: a 2-year, multicenter, real-life observational study. Expert opinion on biological therapy 22 (4) (2022)
Marco Galluzzo, Marina Talamonti, Nicoletta Bernardini, Andrea Chiricozzi, Clara De Simone, Claudio Bonifati, Pierluigi Bruni, Diotallevi Federico, Maria Esposito, Dario Graceffa, Katharina Hansel, Francesco Loconsole, Gaia Moretta, Cristina Mugheddu, Manuela Papini, Antonio Giovanni Richetta, Nevena Skroza, Laura Atzori, Maria-Concetta Fargnoli, Severino Persechino, Annamaria Offidani, Luca Stingeni, Ketty Peris, Concetta Potenza, Luca Bianchi
Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year. Expert opinion on biological therapy (2022)
Marina Talamonti, Marco Galluzzo, Andrea Chiricozzi, Pietro Quaglino, Gabriella Fabbrocini, Paolo Gisondi, Angelo Valerio Marzano, Concetta Potenza, Andrea Conti, Aurora Parodi, Stefano Piaserico, Federico Bardazzi, Giuseppe Argenziano, Franco Rongioletti, Luca Stingeni, Giuseppe Micali, Francesco Loconsole, Maria Teresa Rossi, Maria Rita Bongiorno, Claudio Feliciani, Pietro Rubegni, Paolo Amerio, Maria Concetta Fargnoli, Paolo Pigatto, Paola Savoia, Steven Paul Nisticò, Sandra Giustini, Andrea Carugno, Serafinella Patrizia Cannavo', Giulia Rech, Francesca Prignano, Annamaria Offidani, Maurizio Lombardo, Iris Zalaudek, Luca Bianchi, Ketty Peris
Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study. Expert opinion on biological therapy 21 (2) (2021)
Marco Galluzzo, Marina Talamonti, Valeria Manfreda, Dionisio Silvaggio, Chiara Tartaglia, Denis Roberto, Elena Campione, Luca Bianchi
Impact of secukinumab on patient-reported outcomes in moderate to severe plaque psoriasis: a review of clinical studies. Expert opinion on biological therapy 21 (2) (2021)
Marina Talamonti, Marco Galluzzo, Dionisio Silvaggio, Paolo Lombardo, Chiara Tartaglia, Luca Bianchi
Quality of Life and Psychological Impact in Patients with Atopic Dermatitis. Journal of clinical medicine 10 (6) (2021)
Marina Talamonti, Marco Galluzzo
Safety of COVID-19 vaccines in patients with psoriasis undergoing therapy with anti-interleukin agents. Expert opinion on biological therapy 21 (11) (2021)
S D'Adamio, A Massaro, S Biocca, L Bianchi, Marina Talamonti, Marco Galluzzo
A life with atopic dermatitis: the patient's point of view after a new hope with dupilumab. Clinical and experimental dermatology 45 (6) (2020)
G Caldarola, Federico Pirro, A Di Stefani, Marina Talamonti, Marco Galluzzo, S D'Adamio, M Magnano, N Bernardini, P Malagoli, F Bardazzi, C Potenza, L Bianchi, K Peris, C De Simone
Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature. Expert opinion on biological therapy 20 (6) (2020)
Martina Morelli, Marco Galluzzo, Stefania Madonna, Claudia Scarponi, Giovanni Luca Scaglione, Galluccio Tiziana, Andreani Marco, Sabatino Pallotta, Giampiero Girolomoni, Luca Bianchi, Marina Talamonti, Cristina Albanesi
HLA-Cw6 and other HLA-C alleles, as well as MICB-DT, DDX58, and TYK2 genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis. Expert opinion on biological therapy 21 (2) (2020)
Marina Talamonti, L Tofani, L Bianchi, M Galluzzo
Optimizing care for psoriatic patients requiring systemic therapies: how will COVID-19 disease transform risk perceptions? Archives of dermatological research 313 (2) (2020)
Marco Galluzzo, Lorenzo Tofani, Luca Bianchi, Marina Talamonti
Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era. Expert opinion on biological therapy 20 (8) (2020)
Elena Campione, Caterina Lanna, Laura Diluvio, Maria Vittoria Cannizzaro, Sandro Grelli, Marco Galluzzo, Marina Talamonti, Margherita Annicchiarico-Petruzzelli, Mara Mancini, Gerry Melino, Eleonora Candi, Gianfranco Schiavone, Ying Wang, Yufang Shi, Luca Bianchi
Skin immunity and its dysregulation in atopic dermatitis, hidradenitis suppurativa and vitiligo. Cell cycle (Georgetown, Tex.) 19 (3) (2020)
Marco Galluzzo, Lorenzo Tofani, Paolo Lombardo, Alessandra Petruzzellis, Dionisio Silvaggio, Colin Gerard Egan, Luca Bianchi, Marina Talamonti
Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study. Journal of clinical medicine 9 (7) (2020)
Marco Galluzzo, Simone D'Adamio, Dionisio Silvaggio, Paolo Lombardo, Luca Bianchi, Marina Talamonti
In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis. Expert opinion on biological therapy 20 (2) (2019)
Caterina Lanna, Mara Mancini, Roberta Gaziano, Maria Vittoria Cannizzaro, Marco Galluzzo, Marina Talamonti, Valentina Rovella, Margherita Annicchiarico-Petruzzelli, Gerry Melino, Ying Wang, Yufang Shi, Elena Campione, Luca Bianchi
Skin immunity and its dysregulation in psoriasis. Cell cycle (Georgetown, Tex.) 18 (20) (2019)
Marco Galluzzo, Marina Talamonti, Clara De Simone, Simone D'Adamio, Gaia Moretta, Sara Tambone, Giacomo Caldarola, Maria Concetta Fargnoli, Ketty Peris, Luca Bianchi
Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation. Expert opinion on biological therapy 18 (7) (2018)
Marco Galluzzo, Simone D'Adamio, Luca Bianchi, Marina Talamonti
Psoriasis in pregnancy: case series and literature review of data concerning exposure during pregnancy to ustekinumab. The Journal of dermatological treatment 30 (1) (2018)
Marco Galluzzo, S D'Adamio, E Campione, L Bianchi, Marina Talamonti
A safety evaluation of guselkumab for the treatment of psoriasis. Expert opinion on drug safety 17 (7) (2018)
Marina Talamonti, Simone D'Adamio, Luca Bianchi, Marco Galluzzo
The Role of Pharmacogenetics in Chronic Plaque Psoriasis: Update of the Literature. Molecular diagnosis & therapy 21 (5) (2018)
Marina Talamonti, Marco Galluzzo, J M van den Reek, E M de Jong, J L W Lambert, P Malagoli, L Bianchi, A Costanzo
Role of the HLA-C*06 allele in clinical response to ustekinumab: evidence from real life in a large cohort of European patients. The British journal of dermatology 177 (2) (2017)
Marco Galluzzo, Marina Talamonti, F Perino, S Servoli, D Giordano, S Chimenti, C De Simone, K Peris
Bioelectrical impedance analysis to define an excess of body fat: evaluation in patients with psoriasis. The Journal of dermatological treatment 28 (4) (2016)

Marina Talamonti.css-eqlu8i{font-size:small;padding-left:4px;} (M Talamonti)

Publication Activity (10 Years)

Top Topics

Top Venues

Marina Talamonti (M Talamonti)